Janus Henderson Group PLC Invests $232,000 in Medifast Inc (MED)
Janus Henderson Group PLC bought a new stake in Medifast Inc (NYSE:MED) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,450 shares of the specialty retailer’s stock, valued at approximately $232,000.
Other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in shares of Medifast in the 1st quarter valued at about $125,000. SeaCrest Wealth Management LLC lifted its holdings in shares of Medifast by 37,500.0% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 1,504 shares of the specialty retailer’s stock valued at $241,000 after purchasing an additional 1,500 shares during the last quarter. Balasa Dinverno & Foltz LLC purchased a new stake in shares of Medifast in the 2nd quarter valued at about $260,000. Bank of Montreal Can increased its position in Medifast by 245.4% in the 2nd quarter. Bank of Montreal Can now owns 1,627 shares of the specialty retailer’s stock valued at $261,000 after acquiring an additional 1,156 shares during the period. Finally, Matisse Capital acquired a new position in Medifast in the 2nd quarter valued at about $280,000. 88.54% of the stock is owned by institutional investors and hedge funds.
MED has been the topic of several recent research reports. DA Davidson boosted their price target on Medifast to $201.00 and gave the company a “buy” rating in a research report on Monday, July 23rd. Zacks Investment Research cut Medifast from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 25th. Finally, ValuEngine cut Medifast from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 8th.
Medifast (NYSE:MED) last issued its quarterly earnings results on Thursday, August 2nd. The specialty retailer reported $1.16 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.98 by $0.18. The firm had revenue of $117.30 million for the quarter, compared to analysts’ expectations of $101.75 million. Medifast had a return on equity of 37.25% and a net margin of 10.87%. The firm’s revenue for the quarter was up 55.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.63 EPS. equities analysts expect that Medifast Inc will post 4.5 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, November 8th. Investors of record on Friday, September 21st will be given a $0.48 dividend. This represents a $1.92 annualized dividend and a yield of 0.91%. The ex-dividend date is Thursday, September 20th. Medifast’s dividend payout ratio (DPR) is presently 83.84%.
Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands.
Read More: Stock Symbols and CUSIP Explained
Want to see what other hedge funds are holding MED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medifast Inc (NYSE:MED).
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.